2.00Open2.00Pre Close0 Volume14 Open Interest7.50Strike Price0.00Turnover556.70%IV-78.57%PremiumJan 17, 2025Expiry Date4.42Intrinsic Value100Multiplier22DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.4878Delta0.0952Gamma0.58Leverage Ratio-0.0381Theta-0.0032Rho-0.28Eff Leverage0.0030Vega
Revance Therapeutics Stock Discussion
Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement
Crown Laboratories and Revance Therapeutics (NASDAQ: RVNC) have announced an amended merger agreement where Crown will acquire all outstanding Revance shares for $3.10 per share in cash through a tender offer. The amendment comes after several developments, including Revance's settlement with Teoxane regarding distribution agreements and revised brand guidelines, which are expect...
📊⚡️📊
No comment yet